T2 Biosystems, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2019-11-20: Form 8-K; Period of report 2019-11-20; Description 8.01 Other Events; Details 8.01.
- 2019-11-13: Form 8-K; Period of report 2019-11-12; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2019-09-10: Form 8-K; Period of report 2019-09-10; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2019-09-10: Form 8-K; Period of report 2019-09-06; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2019-11-20 | 8-K | 2019-11-20 | 8.01 Other Events | 8.01 On November 20, 2019 T2 Biosystems, Inc. (the “Company”) issued a press release announcing the granting of a CE-Mark to the T2Resistance™ Panel which will allow the Company to market the T2Resistance Panel within the European Economic Area. | d838072d8k.htm |
| 2019-11-13 | 8-K | 2019-11-12 | 2.02 Results of Operations and Financial Condition | 2.02 On November 12, 2019, T2 Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its fiscal quarter ended September 30, 2019 and held a conference call to discuss those results. | d831518d8k.htm |
| 2019-09-10 | 8-K | 2019-09-10 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d794219d8k.htm |
| 2019-09-10 | 8-K | 2019-09-06 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d798676d8k.htm |
| 2019-08-01 | 8-K | 2019-07-30 | 2.02 Results of Operations and Financial Condition | 2.02 On July 30, 2019, T2 Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its second quarter ended June 30, 2019 and held a conference call to discuss those results. | d748479d8k.htm |
| 2019-07-30 | 8-K | 2019-07-25 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.01 On July 30, 2019, T2 Biosystems, Inc. (the “Company”) entered into an Equity Distribution Agreement (the “Canaccord Sales Agreement”) with Canaccord Genuity LLC (“Canaccord”), pursuant to which the Company may, from time to time, sell shares (the “ATM Shares”) of the Company’s common stock, par value $0.001 per share (“Common Stock”), having an aggregate gross sales amount of up to $30,000,000 through Canaccord, as the Company’s sales agent. 5.02 On July 25, 2019, John McDonough notified the Company of his resignation as President and Chief Executive Officer (“CEO”) of the Company, effective as of the date on which his successor commences employment with the Company or such earlier date as determined by the Board of Directors of the Company (the “Separation Date”). | d783859d8k.htm |
| 2019-06-12 | 8-K | 2019-06-07 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 (a) The Annual Meeting of Stockholders of T2 Biosystems, Inc. (the “Company”) occurred on June 7, 2019. | d25916d8k.htm |
| 2019-05-08 | 8-K | 2019-05-02 | 2.02 Results of Operations and Financial Condition | 2.02 On May 2, 2019, T2 Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its fiscal quarter ended March 31, 2019 and held a conference call to discuss those results. | d929260d8k.htm |
| 2019-03-21 | 8-K | 2019-03-15 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d721459d8k.htm |
| 2019-03-13 | 8-K | 2019-03-07 | 2.02 Results of Operations and Financial Condition | 2.02 On March 7, 2019, T2 Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its fiscal quarter and year ended December 31, 2018 and held a conference call to discuss those results. | d682740d8k.htm |